Intraventricular Delivery and CRISPR-Cas9 Disruption of PD-1 is Required for CAR T-cell Efficacy in Glioblastoma

被引：0
|
作者：
Choi, Bryan D.
Yu, Xiaoling
Nahed, Brian V.
Cahill, Daniel P.
Curry, William T.
Carter, Bob S.
Maus, Marcela V.
机构：
来源：
NEUROSURGERY | 2020年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
823
引用
收藏
页码：286 / 286
页数：1
相关论文
共 50 条
  • [21] Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
    John, Liza B.
    Kershaw, Michael H.
    Darcy, Phillip K.
    ONCOIMMUNOLOGY, 2013, 2 (10)
  • [22] CRISPR-Cas9 applications in T cells and adoptive T cell therapies
    Chen, Xiaoying
    Zhong, Shuhan
    Zhan, Yonghao
    Zhang, Xuepei
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2024, 29 (01)
  • [23] CRISPR-Cas9 T Cell Editing for Finnish Founder Diseases
    Mamia, Katariina
    Li, Zhuokun
    Reint, Ganna
    Fatkhutdinov, Nail
    Haugen, Frida
    Gjerdingen, Thea
    Szymanska, Monika
    Labun, Kornel
    Olweus, Johanna
    Haapaniemi, Emma
    MOLECULAR THERAPY, 2022, 30 (04) : 455 - 455
  • [24] CRISPR-Cas9 Disruption of Aquaporin 1: An Alternative to Glaucoma Eye Drop Therapy?
    Komaromy, Andras M.
    MOLECULAR THERAPY, 2020, 28 (03) : 706 - 708
  • [25] DISRUPTION OF PD-L1 BY ENHANCED TWO-SGRNAS CRISPR/CAS9 IN TREATMENT OF GLIOBLASTOMA
    Fierro, Javier
    Perez, Joshua
    Aguilar, Rocio
    Dipasquale, Jake
    Tran, An
    Factoriza, Chris
    Dou, Huanyu
    NEURO-ONCOLOGY, 2021, 23 : 100 - 100
  • [26] CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer
    Su, Shu
    Zou, Zhengyun
    Chen, Fangjun
    Ding, Naiqing
    Du, Juan
    Shao, Jie
    Li, Lin
    Fu, Yao
    Hu, Bian
    Yang, Yang
    Sha, Huizi
    Meng, Fanyan
    Wei, Jia
    Huang, Xingxu
    Liu, Baorui
    ONCOIMMUNOLOGY, 2017, 6 (01):
  • [27] Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes
    Ferdosi, Shayesteh R.
    Ewaisha, Radwa
    Moghadam, Farzaneh
    Krishnah, Sri
    Park, Jin G.
    Ebrahimkhani, Mo R.
    Kiani, Samira
    Anderson, Karen S.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [28] Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes
    Shayesteh R. Ferdosi
    Radwa Ewaisha
    Farzaneh Moghadam
    Sri Krishna
    Jin G. Park
    Mo R. Ebrahimkhani
    Samira Kiani
    Karen S. Anderson
    Nature Communications, 10
  • [29] Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering
    Hamilton, Jennifer R.
    Tsuchida, Connor A.
    Nguyen, David N.
    Shy, Brian R.
    McGarrigle, E. Riley
    Espinoza, Cindy R. Sandoval
    Carr, Daniel
    Blaeschke, Franziska
    Marson, Alexander
    Doudna, Jennifer A.
    CELL REPORTS, 2021, 35 (09):
  • [30] Broadening the applicability of antigen-specific T-cell immunotherapy by CRISPR-CAS9 inactivation of the glucocorticoid receptor
    Alvanou, M.
    Pantazi, C.
    Koukoulias, K.
    Kouimtzidis, A.
    Vallianou, I.
    Psatha, N.
    Tsiolas, G.
    Spyridonidis, A.
    Stamatopoulos, K.
    Anagnostopoulos, A.
    Makris, A.
    Yannaki, E.
    Papadopoulou, A.
    HUMAN GENE THERAPY, 2019, 30 (11) : A69 - A69
12345